Does LEUPROLIDE Cause Tumour marker increased? 9 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Tumour marker increased have been filed in association with LEUPROLIDE (Fensolvi). This represents 0.0% of all adverse event reports for LEUPROLIDE.
9
Reports of Tumour marker increased with LEUPROLIDE
0.0%
of all LEUPROLIDE reports
0
Deaths
1
Hospitalizations
How Dangerous Is Tumour marker increased From LEUPROLIDE?
Of the 9 reports, 1 (11.1%) required hospitalization.
Is Tumour marker increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LEUPROLIDE. However, 9 reports have been filed with the FAERS database.
What Other Side Effects Does LEUPROLIDE Cause?
Hot flush (9,146)
Death (8,772)
Intercepted product preparation error (8,621)
Syringe issue (7,847)
Device leakage (5,861)
Wrong technique in product usage process (5,062)
Fatigue (4,805)
Injection site pain (4,678)
Prostatic specific antigen increased (2,432)
Asthenia (2,176)
What Other Drugs Cause Tumour marker increased?
PALBOCICLIB (817)
FULVESTRANT (408)
NIRAPARIB (356)
LETROZOLE (343)
RIBOCICLIB (317)
RUCAPARIB CAMSYLATE (257)
CAPECITABINE (228)
EVEROLIMUS (228)
ELACESTRANT (222)
OLAPARIB (171)
Which LEUPROLIDE Alternatives Have Lower Tumour marker increased Risk?
LEUPROLIDE vs LEVALBUTEROL
LEUPROLIDE vs LEVAMISOLE
LEUPROLIDE vs LEVAQUIN
LEUPROLIDE vs LEVEMIR
LEUPROLIDE vs LEVETIRACETAM